Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. As well, these applications extend to the care of animals by veterinarians. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary laser technology.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.
Regulatory bodies that oversee radiation safety include the International Atomic Energy Agency (IAEA), International Commission on Radiological Protection (ICRP), International Commission on Radiation Units and Measurements (ICRU), Food and Drug Administration (FDA) in the US, National Council on Radiation Protection and Measurements (NCRP) in the US, and the Atomic Energy Regulatory Board (AERB) in India. These bodies establish standards and guidelines for safe use of radiation, authorize practices involving radiation sources, inspect facilities, and provide recommendations to ensure radiation protection and safety.
Regulating radiation at levels where no harmful effect is observed baldryLeishman Associates
1) The document discusses regulatory approaches to radiation exposure and outlines challenges in regulating very low doses where risks are difficult to quantify.
2) It argues that regulatory focus on optimizing doses (ALARA principle) may not provide the most value and that non-radiation related priorities like public reassurance, business support, and government confidence should be considered.
3) The author advocates for an outcome-based approach focusing on building trust and relationships rather than theoretical risk reductions from very low doses that cannot be detected. This would better serve stakeholders and give regulators a clearer sense of purpose.
Theralase designs and manufactures patented superpulsed laser technology for biostimulative applications in human, equine, and companion animal medicine. Their laser systems safely and effectively treat pain, inflammation, and musculoskeletal conditions to accelerate healing. Theralase offers clinical research, training, marketing support, and technical support to help practitioners treat conditions and get equine athletes back in competition more quickly. Studies show Theralase laser therapy can reduce inflammation and pain and speed recovery for injuries like tendon strains, improving outcomes for equine veterinary practices and owners.
A case study examines the use of low-level laser therapy (LLT) to treat a patient with traumatic brain injury (TBI) from repeated blows to the head with a lead pipe. The patient experienced severe, daily migraines for two years since the injury. After five 10-minute LLLT treatments over two weeks targeting areas of the scalp and head, the patient's migraine pain was eliminated according to a pain scale. The study suggests LLLT may help address symptoms of TBI through vasodilation and increased blood flow to support metabolic needs in the brain.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
Theralase Technologies Inc. designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.
Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.
Regulatory bodies that oversee radiation safety include the International Atomic Energy Agency (IAEA), International Commission on Radiological Protection (ICRP), International Commission on Radiation Units and Measurements (ICRU), Food and Drug Administration (FDA) in the US, National Council on Radiation Protection and Measurements (NCRP) in the US, and the Atomic Energy Regulatory Board (AERB) in India. These bodies establish standards and guidelines for safe use of radiation, authorize practices involving radiation sources, inspect facilities, and provide recommendations to ensure radiation protection and safety.
Regulating radiation at levels where no harmful effect is observed baldryLeishman Associates
1) The document discusses regulatory approaches to radiation exposure and outlines challenges in regulating very low doses where risks are difficult to quantify.
2) It argues that regulatory focus on optimizing doses (ALARA principle) may not provide the most value and that non-radiation related priorities like public reassurance, business support, and government confidence should be considered.
3) The author advocates for an outcome-based approach focusing on building trust and relationships rather than theoretical risk reductions from very low doses that cannot be detected. This would better serve stakeholders and give regulators a clearer sense of purpose.
Theralase designs and manufactures patented superpulsed laser technology for biostimulative applications in human, equine, and companion animal medicine. Their laser systems safely and effectively treat pain, inflammation, and musculoskeletal conditions to accelerate healing. Theralase offers clinical research, training, marketing support, and technical support to help practitioners treat conditions and get equine athletes back in competition more quickly. Studies show Theralase laser therapy can reduce inflammation and pain and speed recovery for injuries like tendon strains, improving outcomes for equine veterinary practices and owners.
A case study examines the use of low-level laser therapy (LLT) to treat a patient with traumatic brain injury (TBI) from repeated blows to the head with a lead pipe. The patient experienced severe, daily migraines for two years since the injury. After five 10-minute LLLT treatments over two weeks targeting areas of the scalp and head, the patient's migraine pain was eliminated according to a pain scale. The study suggests LLLT may help address symptoms of TBI through vasodilation and increased blood flow to support metabolic needs in the brain.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
Theralase Technologies Inc. designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.
Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
Talk about The Natural Step, the Strategic Framework for Sustainability, presented by Paulo Vodianitskaia at the first TEDx UFPR in Curitiba, March 2013.
10 differences between conventional and strategic sustainability by HapiterraPaulo Vodianitskaia
10 differences between conventional and strategic sustainability are described. While conventional approach often results in greenwashing, go to strategic is wise. Hapiterra adopts a systemic approach for sustainability management.
Theralase Technologies Inc. is focused on developing and commercializing therapeutic laser technology and cancer treatments. They are launching an upgraded laser system called the TLC-2000 in Q1 2014 that will provide recurring revenue through monthly treatment fees. This system has been proven effective in clinical studies for pain, inflammation, and other conditions. Theralase also has patented photo dynamic compounds for non-invasive cancer destruction now undergoing preclinical and clinical trials. The company is seeking a $3M private placement to expand their laser center network internationally and in major US cities starting in 2014 to increase sales of their FDA-approved laser technology.
Paulo Vodianitskaia's presentation as Overview Speaker at the UNEP HFC Management Workshop, Bangkok, 20-21 April 2015. The presentation shows current refrigerant options, recommendations and strategic pathways to help refrigeration industry and policymakers worldwide to promote conversion from Hydrofluorocarbons to low-GWP refrigerants, considering recommendations from a sustainability perspective.
Theralase announced its 2012 year-end financial results, reporting a 10% reduction in total revenue to $1.8 million compared to 2011, primarily due to a decrease in laser sales in the US and internationally. Research and development costs increased 15% to $873,335 as the company focused on developing its next-generation laser and photo dynamic compound cancer destruction technology. The net loss for 2012 was $1.5 million, up from $1.45 million in 2011, due to increases in stock-based compensation and R&D costs. Theralase is preparing to launch its new TLC-2000 laser in 2013 and expects its photo dynamic compound bladder cancer treatment to be ready for human trials in 2014.
More than 350,000 new cases of bladder cancer are diagnosed worldwide each year; the vast majority (> 90%) of these are transitional cell carcinomas (TCC). The most important risk factors for the development of bladder cancer are smoking and occupational exposure to toxic chemicals. Painless visible haematuria is the most common presenting symptom of bladder cancer; significant haematuria requires referral to a specialist urology service. Cystoscopy and urine cytology are currently the recommended tools for diagnosis of bladder cancer. Excluding muscle invasion is an important diagnostic step, as outcomes for patients with muscle invasive TCC are less favourable. For non-muscle invasive bladder cancer, transurethral resection followed by intravesical chemotherapy (
This randomized controlled trial evaluated the effectiveness of low-level laser therapy (LLT) for treating chronic knee pain. 126 patients with knee osteoarthritis were randomly assigned to receive either active laser treatment or sham laser treatment over 12 sessions within 4 weeks. The primary outcome was pain level measured using a visual analog scale (VAS) from 0-10. Results showed that the active laser treatment provided significant pain relief and osteoarthritic improvements compared to the sham laser, with statistical significance of p<0.01 in reduced VAS scores from baseline to 30-day follow-up. The laser treatment was thus found to be an effective adjunctive therapy for chronic knee pain.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neuro musculoskeletal conditions and wound healing. Theralase is currently developing proprietary Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
Low Level Laser Therapy (LLLT) is a fast growing field of medicine recognized by every major industrialized nation in the world, offering painless, non-invasive and highly effective drug-free solutions. Able to treat a plethora of neural muscular skeletal conditions, LLLT is often the only solution that is available to the highly trained practitioner to control disease when conventional therapies have come up lacking.
Theralase designs, develops, and manufactures patented superpulsed laser technology for biostimulative applications in human, equine, and companion animal medicine. The laser technology safely and effectively treats pain, inflammation, and accelerates healing without side effects. Theralase lasers have been proven in over 3,000 clinical studies to treat various conditions and have helped thousands of practitioners worldwide. The laser system provides a turn-key solution with product, support, training and marketing materials to help practices treat patients and increase revenue.
Theralase Technologies announced that its Photo Dynamic Compound (PDC) technology was proven effective in destroying drug-resistant Staphylococcus aureus bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). MRSA infections cause difficult to treat invasive infections in 25% of those infected. Theralase's PDCs achieved an 8 log or 99.999999% kill rate of MRSA in laboratory testing, comparable to complete sterilization. The PDCs maintained sterilizing activity in low oxygen conditions, demonstrating potential applications for destroying other deadly organisms that thrive in low oxygen. Theralase is pursuing early commercialization of the PDC technology through strategic partnerships for sterilization applications.
Theralase announced that its Photo Dynamic Compound (PDC) technology was proven effective in destroying drug-resistant Staphylococcus aureus bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). MRSA infections cause difficult to treat invasive infections in 25% of those infected. Theralase's PDCs achieved an 8 log or 99.999999% kill rate of MRSA in laboratory testing, comparable to complete sterilization. The PDCs maintained sterilizing activity in low oxygen conditions, demonstrating potential applications for destroying other deadly organisms that thrive in low oxygen. Theralase is pursuing early commercialization of this technology through strategic partnerships to develop sterilization applications using its low-cost and
Theralase Technologies Inc. (TSX-V: TLT) announced today the successful results of preclinical studies (in-vitro and in-vivo) demonstrating significant destruction of various brain and colon cancer cell lines. The new proprietary Theralase treatment sharply delayed the tumour progression, when attacked by the Theralase patented light activated Photo Dynamic Compounds (PDCs), signifying a new and broadly promising approach to cancer treatment. When treated with the Theralase PDCs, cancerous mice survived cancer-free for more than 100 days post-treatment, a highly significant milestone.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination. For further information please visit www.theralase.com
Theralase's Photo Dynamic Therapy (PDT) Division, announced today study results proving that its patented Photo Dynamic Compounds (PDCs) were significantly more effective in destroying a human urinary bladder carcinoma cell line than a FDA approved photosensitizer, aminolevulinic acid (ALA).
The document is a quarterly newsletter from Theralase providing updates on their two divisions - Therapeutic Laser Technology (TLT) and Photo Dynamic Therapy (PDT). It discusses upcoming webinars and seminars, corporate updates including the creation of two operating divisions and identification of bladder cancer as the first clinical target for PDT. It also summarizes partnerships, financing activities, and research progress, including the selection of a leading anti-cancer drug candidate and outlining plans for commercialization and growth.
Discover the future of cancer care at Apollo Proton Cancer Centre. Leading the way in medical oncology with advanced treatments for a brighter tomorrow.
Wavelength February 2012 Volume 16 No. 1Jerry Duncan
1) Elekta recently acquired Nucletron, the world leader in brachytherapy, consolidating its position as a complete provider of radiation oncology.
2) Brachytherapy involves placing a radiation source inside or next to the tumor, allowing high doses to be delivered over a short period while minimizing side effects.
3) Brachytherapy is often used in combination with other therapies like surgery and external beam radiation for cancers of the prostate, breast, gynecological organs, and is being studied for use in additional cancers and treatment combinations.
Telemedicine (Information Technology) - Mathankumar.S - VMKVECMathankumar S
The document discusses various medical imaging techniques including their principles, applications, advantages, and disadvantages. It covers X-rays, CT, MRI, PET, ultrasound, mammography, and angiography. CT is described as producing 3D images from 2D X-ray projections taken around the body. MRI uses magnetic fields and radio waves to generate detailed anatomical images without X-rays. PET involves detecting gamma rays emitted from radiotracers to produce functional images. Ultrasound uses sound waves to image tissues based on acoustic impedance.
Talk about The Natural Step, the Strategic Framework for Sustainability, presented by Paulo Vodianitskaia at the first TEDx UFPR in Curitiba, March 2013.
10 differences between conventional and strategic sustainability by HapiterraPaulo Vodianitskaia
10 differences between conventional and strategic sustainability are described. While conventional approach often results in greenwashing, go to strategic is wise. Hapiterra adopts a systemic approach for sustainability management.
Theralase Technologies Inc. is focused on developing and commercializing therapeutic laser technology and cancer treatments. They are launching an upgraded laser system called the TLC-2000 in Q1 2014 that will provide recurring revenue through monthly treatment fees. This system has been proven effective in clinical studies for pain, inflammation, and other conditions. Theralase also has patented photo dynamic compounds for non-invasive cancer destruction now undergoing preclinical and clinical trials. The company is seeking a $3M private placement to expand their laser center network internationally and in major US cities starting in 2014 to increase sales of their FDA-approved laser technology.
Paulo Vodianitskaia's presentation as Overview Speaker at the UNEP HFC Management Workshop, Bangkok, 20-21 April 2015. The presentation shows current refrigerant options, recommendations and strategic pathways to help refrigeration industry and policymakers worldwide to promote conversion from Hydrofluorocarbons to low-GWP refrigerants, considering recommendations from a sustainability perspective.
Theralase announced its 2012 year-end financial results, reporting a 10% reduction in total revenue to $1.8 million compared to 2011, primarily due to a decrease in laser sales in the US and internationally. Research and development costs increased 15% to $873,335 as the company focused on developing its next-generation laser and photo dynamic compound cancer destruction technology. The net loss for 2012 was $1.5 million, up from $1.45 million in 2011, due to increases in stock-based compensation and R&D costs. Theralase is preparing to launch its new TLC-2000 laser in 2013 and expects its photo dynamic compound bladder cancer treatment to be ready for human trials in 2014.
More than 350,000 new cases of bladder cancer are diagnosed worldwide each year; the vast majority (> 90%) of these are transitional cell carcinomas (TCC). The most important risk factors for the development of bladder cancer are smoking and occupational exposure to toxic chemicals. Painless visible haematuria is the most common presenting symptom of bladder cancer; significant haematuria requires referral to a specialist urology service. Cystoscopy and urine cytology are currently the recommended tools for diagnosis of bladder cancer. Excluding muscle invasion is an important diagnostic step, as outcomes for patients with muscle invasive TCC are less favourable. For non-muscle invasive bladder cancer, transurethral resection followed by intravesical chemotherapy (
This randomized controlled trial evaluated the effectiveness of low-level laser therapy (LLT) for treating chronic knee pain. 126 patients with knee osteoarthritis were randomly assigned to receive either active laser treatment or sham laser treatment over 12 sessions within 4 weeks. The primary outcome was pain level measured using a visual analog scale (VAS) from 0-10. Results showed that the active laser treatment provided significant pain relief and osteoarthritic improvements compared to the sham laser, with statistical significance of p<0.01 in reduced VAS scores from baseline to 30-day follow-up. The laser treatment was thus found to be an effective adjunctive therapy for chronic knee pain.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neuro musculoskeletal conditions and wound healing. Theralase is currently developing proprietary Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
Low Level Laser Therapy (LLLT) is a fast growing field of medicine recognized by every major industrialized nation in the world, offering painless, non-invasive and highly effective drug-free solutions. Able to treat a plethora of neural muscular skeletal conditions, LLLT is often the only solution that is available to the highly trained practitioner to control disease when conventional therapies have come up lacking.
Theralase designs, develops, and manufactures patented superpulsed laser technology for biostimulative applications in human, equine, and companion animal medicine. The laser technology safely and effectively treats pain, inflammation, and accelerates healing without side effects. Theralase lasers have been proven in over 3,000 clinical studies to treat various conditions and have helped thousands of practitioners worldwide. The laser system provides a turn-key solution with product, support, training and marketing materials to help practices treat patients and increase revenue.
Theralase Technologies announced that its Photo Dynamic Compound (PDC) technology was proven effective in destroying drug-resistant Staphylococcus aureus bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). MRSA infections cause difficult to treat invasive infections in 25% of those infected. Theralase's PDCs achieved an 8 log or 99.999999% kill rate of MRSA in laboratory testing, comparable to complete sterilization. The PDCs maintained sterilizing activity in low oxygen conditions, demonstrating potential applications for destroying other deadly organisms that thrive in low oxygen. Theralase is pursuing early commercialization of the PDC technology through strategic partnerships for sterilization applications.
Theralase announced that its Photo Dynamic Compound (PDC) technology was proven effective in destroying drug-resistant Staphylococcus aureus bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). MRSA infections cause difficult to treat invasive infections in 25% of those infected. Theralase's PDCs achieved an 8 log or 99.999999% kill rate of MRSA in laboratory testing, comparable to complete sterilization. The PDCs maintained sterilizing activity in low oxygen conditions, demonstrating potential applications for destroying other deadly organisms that thrive in low oxygen. Theralase is pursuing early commercialization of this technology through strategic partnerships to develop sterilization applications using its low-cost and
Theralase Technologies Inc. (TSX-V: TLT) announced today the successful results of preclinical studies (in-vitro and in-vivo) demonstrating significant destruction of various brain and colon cancer cell lines. The new proprietary Theralase treatment sharply delayed the tumour progression, when attacked by the Theralase patented light activated Photo Dynamic Compounds (PDCs), signifying a new and broadly promising approach to cancer treatment. When treated with the Theralase PDCs, cancerous mice survived cancer-free for more than 100 days post-treatment, a highly significant milestone.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination. For further information please visit www.theralase.com
Theralase's Photo Dynamic Therapy (PDT) Division, announced today study results proving that its patented Photo Dynamic Compounds (PDCs) were significantly more effective in destroying a human urinary bladder carcinoma cell line than a FDA approved photosensitizer, aminolevulinic acid (ALA).
The document is a quarterly newsletter from Theralase providing updates on their two divisions - Therapeutic Laser Technology (TLT) and Photo Dynamic Therapy (PDT). It discusses upcoming webinars and seminars, corporate updates including the creation of two operating divisions and identification of bladder cancer as the first clinical target for PDT. It also summarizes partnerships, financing activities, and research progress, including the selection of a leading anti-cancer drug candidate and outlining plans for commercialization and growth.
Discover the future of cancer care at Apollo Proton Cancer Centre. Leading the way in medical oncology with advanced treatments for a brighter tomorrow.
Wavelength February 2012 Volume 16 No. 1Jerry Duncan
1) Elekta recently acquired Nucletron, the world leader in brachytherapy, consolidating its position as a complete provider of radiation oncology.
2) Brachytherapy involves placing a radiation source inside or next to the tumor, allowing high doses to be delivered over a short period while minimizing side effects.
3) Brachytherapy is often used in combination with other therapies like surgery and external beam radiation for cancers of the prostate, breast, gynecological organs, and is being studied for use in additional cancers and treatment combinations.
Telemedicine (Information Technology) - Mathankumar.S - VMKVECMathankumar S
The document discusses various medical imaging techniques including their principles, applications, advantages, and disadvantages. It covers X-rays, CT, MRI, PET, ultrasound, mammography, and angiography. CT is described as producing 3D images from 2D X-ray projections taken around the body. MRI uses magnetic fields and radio waves to generate detailed anatomical images without X-rays. PET involves detecting gamma rays emitted from radiotracers to produce functional images. Ultrasound uses sound waves to image tissues based on acoustic impedance.
LECTUREThe Impact of Technology on Clinical and IT SystemsIn.docxsmile790243
LECTURE
The Impact of Technology on Clinical and IT Systems
Introduction
One of the factors driving change in the health care delivery system is the rapidly evolving technology that emerges from research and development. Emerging technologies create rapid and profound change in the delivery system and may have drastic financial impacts. However, adapting new technologies without a clear understanding of what they can do for and to the system is never a good idea. They must be evaluated for their abilities to enhance the quality of care, along with their capacity to drive new revenue in a procedure-based delivery system. Finally, the cost of new technology is highly correlated with how new it is, and whether it is a stand-alone product with no competition. All of these factors combine to make it essential to do careful business and clinical analyses prior to committing to even the most appealing new technology.
In this module, we will examine two types of new technology: clinical applications and the electronic medical record (EMR).
Clinical Technology
In the realm of clinical technology, there are numerous subgroups. In selected subgroups, we will explore examples of new technology that is in the research and development pipeline.
Cardiovascular
The underlying theme of technology in cardiovascular care is the shift from significantly invasive approaches, such as open cardiac bypass surgery requiring a split sterna surgical approach and the use of a heart lung machine to maintain the patient during surgery, toward minimally invasive or noninvasive techniques. Ultra-wide band radar devices allow the measurement of cardiac output, heart rate, heart rhythm, and patterns of blood flow without any invasion of the body. The device is roughly the size of a deck of cards and can be worn in a shirt pocket without leads or monitor pads. The use of this type of radar-based approach allows noninvasive monitoring without pain or limitation of movement by patients.
Another cardiovascular application is the use of bio-absorbable, drug-eluting stents to open coronary arteries. The old technology required a surgical intervention that involved removing an artery from another part of the body and suturing it to the blocked coronary artery to provide a bridge for blood to flow past the blockage. This generally required hours in the operating room, with a patient on a heart bypass machine, and several days to a week in the intensive care unit after surgery. This has been largely replaced by placing stents or coils in the coronary arteries to hold them open. This is done in the cardiac catheterization lab under sedation or light anesthesia and is accomplished by threading a catheter through the arm or leg vein up to the heart and into the artery. However, historically these types of stents could block up again. The newest technology involves placing a bio-absorbable stent that eventually melts into the arterial wall, along with the drug-eluting aspect, which preven ...
The Impact of Technology on Clinical and IT SystemsIntroduction.docxoreo10
The Impact of Technology on Clinical and IT Systems
Introduction
One of the factors driving change in the health care delivery system is the rapidly evolving technology that emerges from research and development. Emerging technologies create rapid and profound change in the delivery system and may have drastic financial impacts. However, adapting new technologies without a clear understanding of what they can do for and to the system is never a good idea. They must be evaluated for their abilities to enhance the quality of care, along with their capacity to drive new revenue in a procedure-based delivery system. Finally, the cost of new technology is highly correlated with how new it is, and whether it is a stand-alone product with no competition. All of these factors combine to make it essential to do careful business and clinical analyses prior to committing to even the most appealing new technology.
In this module, we will examine two types of new technology: clinical applications and the electronic medical record (EMR).
Clinical Technology
In the realm of clinical technology, there are numerous subgroups. In selected subgroups, we will explore examples of new technology that is in the research and development pipeline.
Cardiovascular
The underlying theme of technology in cardiovascular care is the shift from significantly invasive approaches, such as open cardiac bypass surgery requiring a split sterna surgical approach and the use of a heart lung machine to maintain the patient during surgery, toward minimally invasive or noninvasive techniques. Ultra-wide band radar devices allow the measurement of cardiac output, heart rate, heart rhythm, and patterns of blood flow without any invasion of the body. The device is roughly the size of a deck of cards and can be worn in a shirt pocket without leads or monitor pads. The use of this type of radar-based approach allows noninvasive monitoring without pain or limitation of movement by patients.
Another cardiovascular application is the use of bio-absorbable, drug-eluting stents to open coronary arteries. The old technology required a surgical intervention that involved removing an artery from another part of the body and suturing it to the blocked coronary artery to provide a bridge for blood to flow past the blockage. This generally required hours in the operating room, with a patient on a heart bypass machine, and several days to a week in the intensive care unit after surgery. This has been largely replaced by placing stents or coils in the coronary arteries to hold them open. This is done in the cardiac catheterization lab under sedation or light anesthesia and is accomplished by threading a catheter through the arm or leg vein up to the heart and into the artery. However, historically these types of stents could block up again. The newest technology involves placing a bio-absorbable stent that eventually melts into the arterial wall, along with the drug-eluting aspect, which prevents clot ...
This document describes a new cancer therapy technique using tunable, monochromatic X-rays being developed by the company MXISystems. The technique shows promise in precisely targeting radiation therapy to cancer cells while sparing healthy tissue. However, commercializing the technology faces challenges including high capital costs, lack of supply chain for key components, and investor reluctance over perceived long-term risk. The document applies the framework of accelerated radical innovation to analyze MXISystems' innovation and determine how to accelerate its widespread clinical use by addressing challenges it faces in commercialization.
Wavelength September 2014 Volume 18 No 2Jerry Duncan
The McLaren Health Care system and Barbara Ann Karmanos Cancer Institute have joined forces to create an integrated statewide cancer care network in Michigan. They have selected Elekta's oncology information system, MOSAIQ, to connect their facilities and provide patient-centered, coordinated care across the network. Implementing a common information system with clinical decision support tools and real-time data analytics will help the network standardize care, reduce variability, and monitor and improve quality of care. The goal is to efficiently deliver comprehensive, high-quality cancer treatment throughout the state.
The Business Fame Magazine is honored to present “The Most Prominent Healthcare Solution Providers In 2021” which are adapting novel technologies to meet and exceed the health care standard.
The document discusses five innovative health technologies that have been enabled by support from the Centre for Process Innovation. It describes technologies such as nanoparticles that can enhance radiotherapy treatment for cancer by generating free radicals without needing oxygen. It also discusses an automated device that can check if nasogastric tubes are correctly placed in patients' stomachs to eliminate human errors that have caused deaths. The document emphasizes how innovation centers help move research breakthroughs and ideas to commercialization to develop products that can improve health outcomes.
Theralase Technologies Inc. announced that it has signed an exclusive distribution agreement with Chengdu Disi Industrial Co. Ltd. to distribute Theralase products in mainland China. Under the terms, Chengdu Disi will market, sell, and provide support for Theralase lasers in China, and Theralase will train Chengdu Disi's personnel. Sales estimates for the first year are planned to exceed $1 million USD. The President of Chengdu Disi stated they were impressed by Theralase's technology and are confident they can successfully promote the brand in China.
This document discusses innovations in radiation oncology at Leeds Cancer Centre in the UK. It provides details on:
1) The implementation of Volumetric Modulated Arc Therapy (VMAT) using the Elekta Versa HD system, which reduced treatment time and improved efficiency compared to IMRT.
2) Clinical trials using the Agility multileaf collimator on the Versa HD, which enabled faster stereotactic body radiation therapy (SBRT) for lung cancer.
3) Research collaborations between Leeds Cancer Centre and Elekta to develop and evaluate flattening filter-free high dose rate mode delivery, which further reduced SBRT treatment times.
Global radiation dose management market is expected to reach US$ 785.81 Million by 2030, according to Renub Research. The goal of radiation dose management is to maintain radiation doses for patients undergoing medical imaging as low as reasonably achievable (ALARA), putting their safety first. This is essential for lowering the chance of cancer brought on by radiation exposure. Added patient safety, reduced costs, and greater diagnostic accuracy are all advantages.
Similar to Theralase Inc. Executive Summary 2013 (20)
Theralase designs, develops, and manufactures patented superpulsed laser technology for biostimulative applications in the human, equine, and companion animal markets. Their laser technology is safe and effective for treating pain, inflammation, and other conditions by promoting cellular regeneration and rebalancing sodium-potassium pathways. Over 3,000 clinical studies and testimonials from medical practitioners have proven the effectiveness of Theralase's laser therapy systems.
This meta-analysis reviewed 22 randomized controlled trials involving 1014 patients to determine the effectiveness of low-level laser therapy (LLLT) for pain relief in various joint areas. The average methodological quality score of the trials was 7.96 out of 10. The analysis found that 11 trials reported positive effects of LLLT for pain relief while 11 reported negative effects. However, when pooling the results, the mean weighted difference in pain reduction on a visual analogue scale was 13.96 mm in favor of the active LLLT groups, indicating LLLT provides statistically significant pain relief for joints. Restricting the analysis to trials using energy doses within previously suggested therapeutic windows produced even greater mean pain relief of 19.88-21
Theralase Technologies Inc. announced a non-brokered private placement to raise up to $500,000 CAD by issuing units consisting of shares and warrants at $0.25 per unit. Proceeds will support small animal cancer trials, research on photodynamic compounds, expansion of laser sales and marketing in the US, and commercialization of a new therapeutic laser. Theralase designs and markets patented superpulsed laser technology for biostimulation, biodestruction, pain treatment, and tissue regeneration in humans and animals.
This randomized, placebo-controlled clinical trial evaluated low-level laser therapy (LLLT) for treating chronic knee pain in 126 patients. Patients received 12 treatments over 4 weeks with a therapeutic laser system or sham laser plus standardized chiropractic techniques. The primary outcome was pain level measured by the visual analog scale (VAS). Results showed significant pain relief and osteoarthritic improvements in the therapeutic laser group compared to the sham laser group, demonstrating LLLT's effectiveness for treating chronic knee pain.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. As well, these applications extend to the care of animals by veterinarians. Theralase complies with FDA, Health Canada, CE, ISO-13485 and CSA-601 regulatory approvals to ensure efficacy, safety and quality in manufacture. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
Theralase Technologies Inc. announced its year-end 2011 financial results, reporting stable total revenues of $2,027,058 compared to 2010. Selling expenses increased 55% due to expansion efforts in the US market, while administrative expenses decreased 17%. Research and development costs rose 26% to advance laser and cancer/bacteria destruction technologies. The net loss was $1,453,974 including non-cash expenses, compared to a 2010 net loss of $1,168,350. Subsequent to year-end, Theralase completed a private placement for gross proceeds of $750,000.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination. For further information please visit www.theralase.com 1-866-843-5273
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Outbreak management including quarantine, isolation, contact.pptx
Theralase Inc. Executive Summary 2013
1. CONFIDENTIAL Page 1
Executive Summary – 2013
Company
Theralase Technologies Inc. (TSXV: TLT) designs, develops and manufactures patented, superpulsed laser
technology used in a wide range of biostimulation and biodestruction clinical applications. The Theralase
technology platform targets several diverse healthcare sectors:
Theralase Technologies Inc. is focused on a two‐part strategy:
1. Production, marketing and distribution of the Theralase Superpulsed Laser for sale to health care
practitioners that are dedicated to the treatment of chronic pain, sports injuries and wounds. In 4Q2013,
launch the patented TLC‐2000 biofeedback laser system internationally to provide a quantum leap in
therapeutic laser technology.
2. Commercialization of patented cancer technology through preclinical research, human clinical trials
and regulatory approvals in the direct destruction of cancer.
Science
In 1917, Albert Einstein first published the principle of Light Amplification by Stimulated Emission of
Radiation, or quite simply lasers. In June 1960, Theodoro H. Maiman constructed, using a ruby crystal, the
first operational laser. In 1965, doctors Sinclair, Knoll and Mester pioneered the way for therapeutic
lasers; lasers that do not cut or destroy tissue, but lasers that heal and have a therapeutic curative effect
on tissue. Approximately 3,000 clinical studies worldwide have attested to the beneficial and curative
effects of therapeutic lasers. In the last twenty years, therapeutic lasers have dramatically increased in
power and effectiveness and decreased in cost and size.
Therapeutic laser therapy is a universal way of treating and healing tissue structures, such as: muscles,
tendons, ligaments, joints, connective tissues, bones and skin. There are thousands of tissue conditions
that therapeutic medical lasers can be applied to, such as: pain relief, muscular‐skeletal conditions, nerve
rehabilitation, wound healing, anti‐aging and addiction therapy.
Biodestructive laser therapy uses proprietary laser technology to activate the Photo Dynamic key of
specifically designed Photodynamic Compounds (PDCs) that have an affinity to certain tissue types and
when light activated have the ability to destroy the target cell. There are thousands of potential
applications of this technology including the destruction of: cancer, bacteria and viruses. Theralase has a
worldwide exclusive patent to a platform of PDCs that are unique in that they are activated via a Type 1
reaction that is independent of oxygen, an important characteristic, as solid core tumors (i.e. breast,
bladder, lung, brain, prostate, et cetera) are hypoxic (low oxygen) in nature.
2. CONFIDENTIAL Page 2
Products
1) TLC‐1000 Biomedical Laser Platform (to be phased out by 2014)
The TLC‐1000 therapeutic laser technology is a non‐invasive, superpulsed, dual wavelength, multiple
diode laser system that has three specifically designed probes; a multiple probe used for neural muscular
skeletal conditions, a dermatological probe used for facial and small area treatments and an acupuncture
probe used for stimulation of acupuncture and trigger points. The TLC‐1000 is FDA, Health Canada and CE
approved and is the current lead product in the Company’s US sales and marketing expansion. In
addition, Theralase has product distributors in the Middle East and China.
Theralase provides turnkey support on its technology, enabling customers to deliver safe, effective and
profitable rehabilitation treatments including customer service, clinical training, new applications,
marketing and patient referrals.
2) TLC‐2000 Biofeedback Laser Platform (Launch date: 4Q2013)
The Theralase TLC‐2000 biofeedback laser system is a quantum leap forward in therapeutic laser
technology. The TLC‐2000 is able to measure a patient’s optical profile in a matter of seconds and then
deliver a precise, clinical dosage of energy to their specific condition in a matter of minutes. Clinically
effective dosages specific to optical tissue profiles will be stored in a HIPAA compliant central databank
and be available real time to all practitioners utilizing the TLC‐2000 therapeutic laser. The TLC‐2000 laser
system is also a learning device that remembers the most clinically effective treatments performed by
practitioners and transmits this information to the central databank for the benefit of all users. Theralase
is currently commercializing the technology and plans to introduce the TLC‐2000 laser system to the
international medical market in 4Q2013. Theralase in keeping with its mandate of world‐class customer
service will allow every Theralase customer, the ability to trade up to the new state of the art TLC‐2000
laser system. In order to allow all laser practitioners a common tool to use in the delivery of precision
therapeutic laser treatments, Theralase will allow purchasers of competitive products the ability to trade
up to the TLC‐2000, under certain terms and conditions.
The TLC‐2000 will also be used to launch Theralase into a new business model, the recurring revenue
model; whereby:
Theralase will provide the technology, training, ongoing service and ongoing marketing / customer
referrals for a one time up‐front fee, plus a small portion of each treatment delivered. In this model,
Theralase will partner with medical practitioners by lowering the up‐front cost of the equipment and
participating in each treatment delivered by the practitioner. The equipment will be billed through the
internet; thus, allowing real time payments and control over non‐payment by practitioners.
The Theralase TLC‐2000 biofeedback laser technology is patented in the United States, five European
countries and Canada.
Theralase therapeutic laser systems are manufactured in an ISO‐13485 internationally certified medical
manufacturing facility based in Toronto, Ontario, Canada.
3. CONFIDENTIAL Page 3
3) TLC‐3000 Photodynamic Compound (PDC) / Laser Technology Platform
This technology involves the research and development of Photodynamic Compounds combined and
activated by proprietary biomedical lasers for the selective destruction of cancers, bacteria and viruses.
The clinical applications of this technology may possibly have a significant impact on one of the most
devastating diseases of our time.
Theralase has successfully completed Milestone 1 – in‐vitro Analysis in the R&D of this technology and
has successfully destroyed brain, breast and colon cancer cell lines in an in‐vitro analysis in 2010.
Theralase has successfully completed Milestone 2 – Small Animal in‐vivo preclinical analysis of the PDC
technology, which commenced in 2011 and was successfully completed in 2012.In this phase, complete
destruction of colon cancer in an orthotopic mouse model was achieved with the mice now living cancer
free for over 1 year post treatment.
Theralase is currently pursuing Milestone 3a – Destruction of bladder cancer in an orthotopic animal
model.
Therapeutic Market
Therapeutic laser technology could potentially be used by over 1 million healthcare practitioners and 300
million public consumers in the US and Canada in the next 5 years.
The therapeutic laser market is extremely fragmented with no one company seen as the industry leader.
All companies claim to have the best product in terms of efficacy, often without any scientific research
support. Theralase therapeutic lasers have been tested in gold standard blinded, randomised, controlled
clinical studies and have proven unequivocally that the Theralase therapeutic laser system is clinically and
statistically effective in reducing pain and inflammation in a wide variety of patients. Many of Theralase’s
clinical studies have been peer‐reviewed and accepted for publication in medical journals as well as
presented at international scientific conferences.
Strategic Opportunity:
Theralase plans to introduce a new business mode in therapeutic lasers, the recurring revenue model;
whereby, Theralase will provide the technology, training, service and customer referrals, in exchange for
an upfront fee and monthly usage fee. In this model, Theralase will partner with the medical practitioner
by lowering the up‐front cost of the equipment and participating in each treatment delivered by the
practitioner. The equipment will be billed through the internet; thus allowing real time payments and
control over non‐payment by practitioners. Theralase expects to generate annual recurring revenue of
$48 to $60 million per year within the next 5 years with 8,000 to 10,000 units in operation producing a
minimum monthly revenue stream of $500 per month per laser. This financial model has been
successfully employed by many Fortune 500 companies, including: cell phone, photocopier, satellite and
cable TV industries.
4. CONFIDENTIAL Page 4
Cancer Market
Bladder cancer has been chosen as Theralase’s principal cancer target for its lead PDC compound.
Theralase PDCs have proved to be toxic to bladder cancer cells when light activated (100% kill rate) at
very low effective concentrations.
$3.98 billion is spent annually for Bladder Cancer Treatment in the USA. There are 73,000 new cases and
over 15,000 deaths in the US each year; worldwide 386,000 new bladder cancer cases occur annually.
Bladder cancer is the most expensive cancer to treat with a recurrence rate of up to 80%. Standard
treatment has remained relatively unchanged with no new drugs approved since 1998.
Strategic Opportunity:
Completion of a FDA Phase 1/2a clinical study in bladder cancer within 3 years. Theralase would then
move to sell all rights to the bladder cancer PDC technology to a pharmaceutical company for a milestone
payment of between $113 to $362 million, research and development costs and would include an annual
royalty stream of $50 to 60 million for 17 years.
Sales
To roll‐out the TLC‐2000 Biofeedback Laser Platform, Theralase will implement a US and Canadian sales
strategy which focuses on establishing beach heads through physical locations in each of the 5 largest US
states and 2 largest Canadian provinces by population; California, New York, Illinois, Texas, Florida,
Alberta and Ontario. A 1500 to 2000 square foot leased property will be secured in each of the major
cities of these territories and employ a full time receptionist, clinic manager, multidisciplinary
practitioners (revenue sharing basis) and a Territory Sales Manager (TSM). The clinic manager will be
responsible for clinic sales, while the TSM will be responsible for product sales. The property will provide
multiple functions in one location; including: a multidisciplinary clinic used to generate brand awareness
and clinic sales to offset the overhead of the facility, provide a training and teaching location for new
practitioners, provide a service depot for product warranty exchanges and provide a sales location for the
TSM to generate product sales and build a distribution network of sales professionals to sell the
Company’s products on a commission basis.
These 7 TSM’s will be supported by the Company with:
1) Affiliation with well‐known teaching hospitals, chiropractic, physical therapist and medical doctor
teaching universities and colleges to provide high‐level clinical and testimonial support
3) Regional and national sales and marketing programs focused on bringing healthcare practitioners to
the clinic to learn about the technology and become a “Theralase Certified Laser Center” in their area
4) National and regional marketing to patients about the benefits of therapeutic laser technology
including a presence at major healthcare and industry conferences
5) Seminar and Webinar series to present Theralase’s technology to healthcare practitioners
5. CONFIDENTIAL Page 5
Key Employees and Advisors
Roger Dumoulin‐White, P.Eng, President and CEO
Mr. Dumoulin‐White founded Theralase in 1995 and has over 25 years as a senior manager with private
and public companies. As an award‐winning entrepreneur, he has pioneered Low‐Level Laser Therapy for
use in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and
wound healing. He is responsible for developing patented Photo Dynamic Compounds (PDCs) that are
able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary
laser technology.
Kristina Hachey, CGA, CFO
Ms. Hachey has over 16 years of experience in finance and financings in public and private companies.
Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer
Dr. Mandel has over 20 years of experience as a key founder of therapeutic uses of lasers in dermatology
and other areas of clinical medicine. He is an experienced executive manager of research and
development teams dedicated to the field of biotechnology, drug development and photobiology. He has
published over 100 original scientific papers to his name, combined with over 200 international patents
attributed to his research. He is an editor of many peer reviewed scientific and medical journals.
Lothar Lilge, Ph.D., Professor in the Department of Medical Biophysics, University of Toronto, Senior
Scientist at the Ontario Cancer Institute / Princess Margaret Cancer Centre / University Health Network
Dr. Lilge's research is focused on photodynamic therapy (PDT), optical diagnostics, destruction of cancer
and bacteria by light activated PDTs and the use of light as a microscopic tool for biomedical research. He
has published over 30 original scientific papers and is an editor of peer reviewed scientific journals. Dr.
Lilge is a much sought after speaker at many international medical and scientific conferences.
Michael Jewett, MD, FRCSC, FACS, Professor of Surgery in the Division of Urology at the University of
Toronto, a member of the Department of Surgical Oncology at Princess Margaret Cancer Centre and of
the Division of Urology at the University Health Network. He is a member of Theralase’s Medical and
Scientific Advisory Board. Dr. Jewett is internationally known for his contributions in the fields of bladder,
testis and kidney cancer fundamental and clinical research. He has been the Principal Investigator/Co‐
Principal Investigator on over 60 Phase I‐Phase III clinical trials and the Lead Principal Investigator of
several Cooperative Group Trials. These clinical trials have primarily been focused on proving the safety,
efficacy and clinical benefits of technology in the destruction of cancer, with the ultimate goal of
achieving FDA or Health Canada clinical approval. He is a recent Past‐President of the Canadian Urology
Association and a member of many urological and surgical oncology societies worldwide. Dr. Jewett has
published over 175 original medical research papers.
James Andrews, MD, Founding member of Andrews Sports Medicine and Orthopaedic Center in
Birmingham, Alabama. He is also a founder of the American Sports Medicine Institute (ASMI) a non‐profit
institute dedicated to injury prevention, education and research in orthopaedics and sports medicine. He
is a member of Theralase’s Medical and Scientific Advisory Board. Doctor Andrews is internationally
known and recognized for his skills as an orthopaedic surgeon as well as his scientific and clinic research
contributions in knee, shoulder and elbow injury prevention and treatment. Doctor Andrews is Senior
Consultant for the Washington Redskins Professional Football team and Medical Director for the Tampa
Bay Rays Professional Baseball Team and the Ladies Professional Golf Association.